Introduction

Meningiomas are primarily considered tumors of the adult population, yet they manifest with distinct biological and clinical behaviors when they occur in children. In the pediatric demographic, these neoplasms account for a very small percentage of all primary central nervous system tumors. Because of their rarity, clinicians often face challenges in characterizing the typical clinical trajectory and long-term Pediatric meningioma clinical outcomes. A significant 10-year retrospective analysis of 198 pediatric patients has recently shed light on these rare occurrences, providing a robust dataset to understand how these tumors differ from those seen in adults. This study focuses on the clinical, radiological, and pathological profiles of patients under 18 years old, treated over a decade. By examining such a large cohort, researchers can identify specific prognostic factors that dictate tumor recurrence and survival. Understanding these nuances is essential for neurosurgeons and oncologists in India and globally to tailor treatment strategies that balance aggressive tumor control with the preservation of neurodevelopmental health. This article explores the findings of this cohort and the implications for modern clinical practice.

Unique Epidemiological and Clinical Manifestations

Pediatric meningiomas exhibit several epidemiological features that contrast sharply with adult cases. While adult meningiomas show a strong female predominance, pediatric cohorts often demonstrate a more balanced gender distribution or even a slight male preponderance. Furthermore, the clinical presentation in children is frequently characterized by signs of increased intracranial pressure rather than localized neurological deficits. Specifically, children commonly present with persistent headaches, vomiting, and papilledema, which reflect the often large size of these tumors at the time of diagnosis. Seizures are also a frequent presenting symptom, occurring in a significant portion of the pediatric population. Notably, these tumors in children are more likely to be associated with genetic syndromes, particularly Neurofibromatosis Type 2 (NF2). Consequently, when a clinician identifies a meningioma in a young child, they must maintain a high index of suspicion for underlying genetic predispositions. Moreover, the anatomical distribution often includes unusual sites, such as the intraventricular compartments or the posterior fossa, which are less common in older patients. These distinct characteristics necessitate a specialized approach to diagnosis and initial stabilization, ensuring that the child’s unique physiological needs are met throughout the diagnostic workup.

Pediatric Meningioma Clinical Outcomes and Resection Strategies

The cornerstone of managing these tumors remains surgical intervention, with the primary goal being gross total resection. Achieving a high Simpson grade resection is the most critical determinant of favorable Pediatric meningioma clinical outcomes. However, the complexity of the pediatric skull and the proximity of tumors to critical vascular structures can complicate the surgical approach. Surgeons must navigate the delicate balance between radical removal and the avoidance of postoperative morbidity. In many cases, the use of advanced neuro-navigation and intraoperative monitoring has improved the safety of these procedures. Despite these technological advancements, subtotal resection remains a reality for tumors involving the skull base or major venous sinuses. Furthermore, the physiological impact of significant blood loss during surgery is a major concern in smaller children. Therefore, meticulous preoperative planning and multidisciplinary coordination are vital. When surgeons achieve complete resection, the long-term prognosis is generally excellent for low-grade tumors. Conversely, cases requiring subtotal resection often necessitate closer surveillance and potentially adjuvant therapies. The data from the 10-year cohort reinforces that the extent of surgical removal is a leading predictor of how well a child will fare in the years following their initial diagnosis.

Radiological Characteristics and Diagnostic Grading

Imaging plays a pivotal role in the management of pediatric meningiomas, from initial detection to long-term surveillance. Magnetic Resonance Imaging (MRI) with contrast is the gold standard, typically revealing well-circumscribed, intensely enhancing extra-axial masses. In the pediatric population, these tumors often present with more aggressive radiological features, such as significant peritumoral edema or bony invasion. Furthermore, the presence of cystic components is more frequently reported in children than in adults. From a histopathological perspective, pediatric meningiomas tend to have a higher incidence of WHO Grade II (atypical) and Grade III (anaplastic) classifications. This higher pathological grade is a significant departure from the adult experience, where Grade I tumors predominate. Consequently, the radiological suspicion of high-grade features must guide the surgical and oncological planning. Specifically, the presence of heterogeneous enhancement or irregular tumor borders on MRI may alert the clinician to a potentially more aggressive subtype. Additionally, diagnostic grading now increasingly incorporates molecular markers, though histopathology remains the primary tool for classification in many clinical settings. Accurately grading these tumors is essential for predicting behavior and determining the intensity of the follow-up regimen.

Identifying Recurrence Predictors in Young Patients

Despite successful initial surgeries, tumor recurrence remains a significant hurdle in pediatric neuro-oncology. The 10-year cohort study identified several key independent prognostic factors that correlate with an increased risk of the tumor returning. Specifically, the World Health Organization (WHO) grade of the tumor and the extent of the initial surgical resection are the most powerful predictors of recurrence. High-grade tumors, such as atypical or anaplastic meningiomas, exhibit a much higher propensity for regrowth compared to benign Grade I lesions. Furthermore, the study highlighted that patients with NF2-associated meningiomas often face multiple recurrences or the development of new primary tumors over time. Consequently, these high-risk patients require a more frequent imaging schedule. Another factor under investigation is the Ki-67 proliferative index, which may serve as a biological marker for aggressive behavior even in seemingly benign tumors. Therefore, clinicians must integrate pathological, surgical, and genetic data to create a personalized risk profile for each patient. By identifying those at highest risk early, medical teams can implement more aggressive surveillance or consider early adjuvant treatments, such as radiotherapy, to mitigate the risk of clinical deterioration from recurrent disease.

The Role of Genetic Syndromes and Future Directions

The association between pediatric meningiomas and genetic syndromes, particularly Neurofibromatosis Type 2, cannot be overstated. In many pediatric series, a significant percentage of patients harbor germline mutations that predispose them to meningiomas, schwannomas, and ependymomas. These syndromic cases often present at an earlier age and may involve multiple tumor sites. Therefore, genetic counseling and screening are mandatory components of the care pathway for children diagnosed with meningiomas. Furthermore, recent advances in molecular profiling are beginning to identify specific genetic alterations, such as NF2 mutations or TRAF7 and KLF4 variants, which may eventually lead to targeted pharmacological therapies. Currently, while surgery and radiation remain the mainstays of treatment, the potential for precision medicine offers hope for cases that are surgically unresectable or resistant to conventional radiation. Future research must focus on multicenter collaborations to increase the sample size of these rare tumors, allowing for more definitive conclusions regarding the efficacy of emerging systemic agents. As we move forward, the integration of molecular diagnostics into routine clinical practice will likely refine our prognostic models and improve the overall quality of life for survivors of pediatric meningiomas.

Frequently Asked Questions

How do pediatric meningiomas differ from adult meningiomas?

Pediatric meningiomas are rare and often present with a more balanced gender distribution than the female-predominant adult cases. They are frequently associated with genetic syndromes like NF2 and are more likely to be high-grade (WHO Grade II or III) and located in unusual areas like the ventricles.

What is the most important factor in preventing recurrence?

The extent of surgical resection, often measured by the Simpson grading system, is the most critical factor. Achieving gross total resection significantly reduces the risk of recurrence. However, the tumor's pathological grade also plays a major role in determining how likely it is to return.

Is radiotherapy commonly used for children with meningiomas?

Radiotherapy is generally reserved for high-grade (WHO Grade II or III) tumors, recurrent cases, or situations where only subtotal resection is possible. Clinicians often try to delay or avoid radiation in very young children due to the potential for long-term neurocognitive and endocrine side effects.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ma J et al. Distinct clinical characteristics and prognostic factors of pediatric meningiomas in a 10-year cohort of 198 patients. Neurosurg Rev. 2026 Jul 13. doi: 10.1007/s10143-026-04395-7. PMID: 42437860.

Xu S, Yang W, Zhang H, et al. Pediatric meningioma: clinical features, radiological findings and surgical outcomes. Childs Nerv Syst. 2023;39(1):143-153. doi:10.1007/s00381-022-05704-w.

Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12(13):1229-1239. doi:10.1016/S1470-2045(11)70275-3.